Trade Cytokinetics Inc - CYTK CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.15 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.023401% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.001179% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 0.1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 39.04 |
| Open | 38.8 |
| 1-Year Change | -43.76% |
| Day's Range | 38.38 - 39.4 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Apr 17, 2025 | 39.40 | 1.40 | 3.68% | 38.00 | 39.42 | 38.00 |
| Apr 16, 2025 | 39.04 | 0.95 | 2.49% | 38.09 | 39.23 | 37.69 |
| Apr 15, 2025 | 38.47 | -0.06 | -0.16% | 38.53 | 40.10 | 37.98 |
| Apr 14, 2025 | 39.74 | 0.84 | 2.16% | 38.90 | 39.93 | 38.01 |
| Apr 11, 2025 | 38.57 | 1.59 | 4.30% | 36.98 | 39.25 | 36.50 |
| Apr 10, 2025 | 37.80 | 1.72 | 4.77% | 36.08 | 38.30 | 35.13 |
| Apr 9, 2025 | 37.19 | 3.73 | 11.15% | 33.46 | 38.85 | 32.71 |
| Apr 8, 2025 | 34.56 | -1.39 | -3.87% | 35.95 | 38.61 | 34.19 |
| Apr 7, 2025 | 35.93 | 0.72 | 2.04% | 35.21 | 37.80 | 34.11 |
| Apr 4, 2025 | 37.26 | -2.52 | -6.33% | 39.78 | 40.29 | 36.83 |
| Apr 3, 2025 | 40.47 | 1.57 | 4.04% | 38.90 | 41.95 | 38.90 |
| Apr 2, 2025 | 40.17 | -1.58 | -3.78% | 41.75 | 43.42 | 40.10 |
| Apr 1, 2025 | 37.44 | -2.75 | -6.84% | 40.19 | 40.36 | 37.41 |
| Mar 31, 2025 | 40.11 | -1.88 | -4.48% | 41.99 | 42.04 | 39.75 |
| Mar 28, 2025 | 43.13 | 0.28 | 0.65% | 42.85 | 43.28 | 41.65 |
| Mar 27, 2025 | 42.91 | -0.67 | -1.54% | 43.58 | 43.86 | 42.65 |
| Mar 26, 2025 | 43.58 | -0.60 | -1.36% | 44.18 | 44.44 | 42.85 |
| Mar 25, 2025 | 44.50 | -1.35 | -2.94% | 45.85 | 45.85 | 43.82 |
| Mar 24, 2025 | 46.48 | 1.10 | 2.42% | 45.38 | 48.24 | 45.38 |
| Mar 21, 2025 | 45.36 | 2.90 | 6.83% | 42.46 | 46.90 | 42.45 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 3:1
- 5:1
- 10:1
- 20:1
- 20
- 100
- 500
- 1000
- 10000
Cytokinetics Inc Company profile
About Cytokinetics, Inc.
Cytokinetics, Incorporated is a late-stage biopharmaceutical company that is focused on discovering, developing and commercializing muscle activators and muscle inhibitors as potential treatments for debilitating diseases. The Company is developing small molecule drug candidates specifically engineered to impact muscle function and contractility. The Company is conducting METEORIC-HF, a second Phase III clinical trial of omecamtiv mecarbil. It is also developing aficamten, a cardiac myosin inhibitor, for the potential treatment of HCM. The Company also conducts research and development on novel treatments for disorders involving muscle function beyond muscle contractility. The Company’s lead drug candidates in clinical development are omecamtiv mecarbil, a cardiac myosin activator; CK-136, a cardiac troponin activator; reldesemtiv, a fast-skeletal muscle troponin activator (FSTA) and CK-3773274 (CK-274), a cardiac myosin inhibitor.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Cytokinetics, Inc. revenues increased 26% to $70.4M. Net loss increased 69% to $215.3M. Revenues reflect License revenues increase of 50% to $54.9M, Milestone revenues increase of 79% to $5M. Higher net loss reflects Research and development increase of 66% to $149.5M (expense), Other General and administrative increase of 91% to $80.4M (expense).
Equity composition
Common Stock $.001 Par, 02/11, 170M auth., 66,910,100 o/s. Insiders and Straegic holds 9.82%. 4/29/04, 5,800,000 shares @ $13 per share by Goldman, Sachs & Co. 25/13, 1-for-6 Reverse Stock split.
| Industry: | Bio Therapeutic Drugs |
350 Oyster Point Boulevard
SOUTH SAN FRANCISCO
CALIFORNIA 94080
US
News
ECB interest-rate forecasts – Projections for the next five years
The European Central Bank (ECB) plays a pivotal role in the economic stability of the eurozone, meaning ECB interest-rate forecasts are key to understanding how financial and economic scenarios might evolve.
14:37, 10 April 2025
BlackRock shareholders: Who owns the most BLK stock?
BlackRock is the leading asset manager in the world – but who are its biggest shareholders? Read on to find out.
13:46, 9 April 2025
Bitcoin price predictions 2025–2050: third-party price target
We examine bitcoin price predictions for 2025 and beyond, with insights from third-party analysts and market experts.
10:28, 9 April 2025
Tesla (TSLA) stock forecast 2025 and beyond: third-party Tesla price target
Where will Tesla’s stock be in five years? Can the EV company keep its crown?
08:19, 9 April 2025
JasmyCoin price predictions 2025-2030: Third-party price target
How might JASMY behave in the future?
16:13, 8 April 2025
Australian interest-rate projections: where will rates be in 5 years?
As one of the most closely watched economic indicators, Australian interest-rate projections offer valuable insight into the future of the country’s economy.
21:37, 7 April 2025
Copper price forecast: third-party price target
What’s next for the copper market? Read on for the latest analysis of the commodity's price and potential outlook.
17:31, 14 March 2025People also watch
Still looking for a broker you can trust?
Join the 720,000+ traders worldwide that chose to trade with Capital.com